Centilo

QTc Prolongation in Children: Causes, Formulas, and Clinical Decision-Making

By Daniel Diaz-Gil, MD· April 2026 · 18 min read

Introduction

QT interval prolongation predisposes children to potentially life-threatening ventricular arrhythmias, particularly torsades de pointes (TdP). Congenital long QT syndrome (LQTS) is an important cause of sudden cardiac death in young individuals, while acquired QT prolongation from medications and electrolyte abnormalities is more common in clinical practice. Accurate QTc measurement, appropriate formula selection, and recognition of high-risk features are essential for pediatric clinicians.

Normal QTc Values by Age

In infants and children, the upper limit of normal for QTc is generally considered to be 460 ms. Key age-specific considerations:

  • Neonates (first week): QTc up to 460 ms may be normal; values >470 ms warrant investigation. An estimated 10% of sudden infant death syndrome is thought to result from hereditary QT prolongation.
  • Children (11 days to 16 years): The 98th percentile limit for QTc is approximately 450 ms in children younger than 12 years.
  • Adolescents: Sex differences emerge during puberty, when the rate-adjusted QT shortens in boys (possibly as a testosterone effect) but undergoes little change in girls. Post-pubertal thresholds: >450 ms in males and >460 ms in females is prolonged.

Risk Thresholds

  • QTc >500 ms: Substantially increased risk for TdP and sudden cardiac death; requires urgent evaluation.
  • QTc 460-500 ms: Warrants monitoring, especially with concurrent QT-prolonging medications or electrolyte abnormalities.
  • QTc <300 ms: Short QT interval may also be associated with malignant arrhythmias.

QT Correction Formulas: Bazett vs. Fridericia

Bazett Formula: QTc = QT / √RR

The Bazett formula is most commonly used in pediatric practice because it matches most reference data and historical literature. However, it has well-documented limitations: it overcorrects at high heart rates and undercorrects at low heart rates, reducing accuracy in tachycardic infants or bradycardic older children.

Fridericia Formula: QTc = QT / ³√RR

The Fridericia formula performs better at heart rate extremes. A 2020 study of 332 healthy children found that during postural maneuvers (which increased heart rate), Bazett correction led to QTc increases from 425 ms (supine) to 445 ms (standing), while Fridericia showed minimal changes. At standing, Bazett identified 151 children with QTc 440-460 ms and 45 with QTc 460-480 ms, while Fridericia identified fewer than 7 children with QTc 440-460 ms and none with longer QTc.

Practical Recommendations

  • Bazett remains appropriate for routine pediatric screening when heart rate is within normal range, as most reference data and diagnostic criteria (including the Schwartz score) use Bazett correction.
  • Fridericia should be considered when heart rate is significantly abnormal (<60 or >90 bpm) or when Bazett-corrected QTc is borderline.
  • A 2025 study of 3,672 young athletes (ages 11-16) found that using both Bazett and Fridericia formulas is recommended for cardiovascular screening, with Fridericia showing no significant differences by age in this population.

Use the QTc Calculator to compute both values side by side.

Diagnosing Congenital Long QT Syndrome

The diagnosis of LQTS should not rely solely on QTc duration but rather on a combination of findings including QT prolongation, clinical features, and family history, as outlined by the Schwartz score.

Schwartz Score Components

ECG Findings:

  • QTc ≥480 ms: 3 points
  • QTc 460-479 ms: 2 points
  • QTc 450-459 ms (males): 1 point
  • QTc ≥480 ms at 4-minute recovery from exercise stress test: 1 point
  • Torsades de pointes: 2 points
  • T-wave alternans: 1 point
  • Notched T wave in 3 leads: 1 point
  • Low heart rate for age (<2nd percentile): 0.5 points

Clinical History:

  • Syncope with stress: 2 points
  • Syncope without stress: 1 point
  • Congenital deafness: 0.5 points

Family History:

  • Family member with definite LQTS: 1 point
  • Unexplained sudden cardiac death age <30 years among immediate family members: 0.5 points

Score Interpretation:

  • ≤1 point: Low probability
  • 1.5-3 points: Intermediate probability
  • ≥3.5 points: High probability (specificity 99%, sensitivity 19-36%)

LQTS is definitively diagnosed with a Schwartz score ≥3.5, presence of a pathogenic variant, or repeated QTc ≥500 ms in the absence of QT-prolonging drugs.

Genotype-Phenotype Correlations

The three most common LQTS subtypes have distinct clinical phenotypes, triggers, and treatment responses:

LQT1 (KCNQ1, ~40-45%): Most common subtype. Arrhythmias triggered by adrenergic stimulation, particularly strenuous exercise (especially swimming) and emotional stress. Beta-blockers are highly effective (>95% reduction in adverse events). Left cardiac sympathetic denervation (LCSD) is particularly effective. ICD rarely needed for primary prevention.

LQT2 (KCNH2, ~25-30%): Arrhythmias triggered by sudden auditory stimuli (alarm clocks, phone ringing), emotional stress, and low potassium levels. Females are at higher risk, particularly in the postpartum period. Recommendations include maintaining serum potassium ≥4 mmol/L, removing telephones and alarm clocks from bedrooms, and taking beta-blockers morning and evening.

LQT3 (SCN5A, ~5-10%): Events typically occur at rest or during sleep, often bradycardia-dependent. Beta-blockers are less effective. Sodium channel blockers (mexiletine, ranolazine, flecainide) shorten QTc and reduce recurrent arrhythmias. Consider home AED and bedroom sharing for sleep protection.

Management of Congenital LQTS

The AHA/ACC/HRS 2017 guidelines recommend that beta-blocker therapy is indicated for patients with LQTS and resting QTc >470 ms (Class I, Level B-NR). In asymptomatic patients with QTc <470 ms, chronic beta-blocker therapy is reasonable (Class IIa). For high-risk patients with symptomatic LQTS in whom beta-blockers are ineffective or not tolerated, intensification of therapy with additional medications (guided by LQTS type), left cardiac sympathetic denervation, and/or ICD is recommended.

High-risk features include: QTc ≥500 ms, LQT2 or LQT3 genotype, females with LQT2, males with LQT3, onset of symptoms at <10 years of age, and prior cardiac arrest or recurrent syncope.

Genetic counseling and genetic testing are recommended for all patients with clinically diagnosed LQTS (Class I). The yield of genetic testing in phenotype-positive patients is 50-86%. QT-prolonging medications are potentially harmful in patients with LQTS (Class III: Harm).

ICD Indications in Pediatric LQTS

The 2021 PACES Expert Consensus Statement provides specific pediatric ICD recommendations:

  • ICD indicated (Class I): LQTS survivors of sudden cardiac arrest; LQTS patients with symptoms (arrhythmic syncope or VT) in whom beta-blockers are ineffective or not tolerated and LCSD or other medications are not effective alternatives
  • ICD may be considered (Class IIb): Primary prevention in LQTS patients with established clinical risk factors and/or pathogenic mutations
  • ICD not indicated (Class III: Harm): Asymptomatic LQTS patients deemed low risk who have not been tried on beta-blocker therapy

Acquired QTc Prolongation

Acquired QT prolongation is more common than congenital LQTS in clinical practice. Drug-induced TdP is rare in patients without risk factors but can be fatal.

Common QT-Prolonging Drug Classes

  • Antiarrhythmics: Sotalol, amiodarone, flecainide, dofetilide, ibutilide, procainamide, quinidine
  • Antipsychotics: Haloperidol, thioridazine, chlorpromazine, risperidone, olanzapine, ziprasidone
  • Antibiotics: Macrolides (azithromycin, erythromycin, clarithromycin), fluoroquinolones (levofloxacin, moxifloxacin, ciprofloxacin)
  • Antiemetics: Ondansetron, domperidone, metoclopramide
  • Antidepressants: Citalopram, escitalopram, tricyclic antidepressants
  • Other: Methadone, pentamidine, chloroquine/hydroxychloroquine

A 2025 pediatric study found QTc prolongation (>450 ms) in 4.2-5.4% of children taking SSRIs, with a positive correlation between norfluoxetine (fluoxetine metabolite) serum levels and QTc duration.

Risk Factors for Drug-Induced TdP

  • QTc >500 ms or QTc lengthening ≥60 ms from baseline
  • Female sex
  • Bradycardia
  • Hypokalemia, hypomagnesemia, hypocalcemia
  • Heart failure
  • Concomitant use of ≥2 QT-prolonging drugs
  • History of drug-induced TdP
  • Genetic predisposition (nearly 30% of patients with drug-induced QT prolongation carry mutations for LQTS genes)

Electrolyte Abnormalities

Hypokalemia, hypocalcemia, and hypomagnesemia substantially amplify drug-induced QTc risk. In patients taking QT-prolonging drugs, serum potassium and magnesium should be maintained at >4.0 mEq/L and >2.0 mg/dL, respectively.

Management of Acquired QT Prolongation

  1. Baseline ECG before starting high-risk medications
  2. Repeat ECG at steady state (typically 3-5 days) and after dose increases
  3. Correct electrolyte abnormalities before and during therapy
  4. Avoid concurrent QT-prolonging agents when possible
  5. Drug discontinuation thresholds: QTc >500 ms requires discontinuation unless essential for survival; QTc increase ≥60 ms from baseline warrants strong consideration for discontinuation; QTc 480-500 ms requires close monitoring, consider dose reduction or alternative agent
  6. Maintain potassium ≥4.0 mEq/L and magnesium ≥2.0 mg/dL in patients on QT-prolonging drugs

Monitoring Recommendations

For children on QT-prolonging medications or with family history of sudden death, serial ECGs are recommended. The AHA recommends QTc monitoring for:

  • Patients with congenital LQTS and unstable ventricular arrhythmias
  • Patients with medically or metabolically induced QTc prolongation until stabilization
  • Patients with moderate to severe hypokalemia or hypomagnesemia combined with other TdP risk factors
  • Patients with drug overdose involving drugs with known TdP risk

Consult CredibleMeds for updated lists of QT-prolonging drugs.

Key Clinical Priorities

  1. Use age-appropriate QTc thresholds: >460 ms is generally prolonged in children; >500 ms carries substantial arrhythmia risk.
  2. Consider Fridericia correction when heart rate is significantly abnormal or Bazett QTc is borderline.
  3. Apply the Schwartz score for systematic LQTS diagnosis — do not rely on QTc alone.
  4. Recognize genotype-specific triggers: Exercise/swimming (LQT1), sudden noises (LQT2), rest/sleep (LQT3).
  5. Beta-blockers are first-line therapy for LQTS; nadolol and propranolol are preferred over metoprolol.
  6. Maintain electrolytes (K+ >4.0 mEq/L, Mg2+ >2.0 mg/dL) in patients on QT-prolonging drugs.
  7. Obtain baseline ECG before starting high-risk medications; repeat at steady state.
  8. Refer urgently any child with QTc >460 ms, syncope, and family history of sudden death.
  9. Genetic testing and counseling are recommended for all patients with clinically diagnosed LQTS.
  10. Early recognition and appropriate intervention prevent sudden cardiac death in children with both congenital and acquired QT prolongation.

References

  1. Buratti G, Shrestha S, Donne M, Katta P. Approach to Prolonged QT Interval in Paediatric and Neonatal Patients. Eur J Pediatr. 2025;184(12):778.
  2. Krahn AD, Laksman Z, Sy RW, et al. Congenital Long QT Syndrome. JACC Clin Electrophysiol. 2022;8(5):687-706.
  3. Sandau KE, Funk M, Auerbach A, et al. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation. 2017;136(19):e273-e344.
  4. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part IV. J Am Coll Cardiol. 2009;53(11):982-991.
  5. Phan DQ, Silka MJ, Lan YT, Chang RK. Comparison of Formulas for Calculation of the Corrected QT Interval in Infants and Young Children. J Pediatr. 2015;166(4):960-964.
  6. Andrsova I, Hnatkova K, Helanova K, et al. Problems With Bazett QTc Correction in Paediatric Screening of Prolonged QTc Interval. BMC Pediatr. 2020;20(1):558.
  7. Mahendran S, Gupta I, Davis J, et al. Comparison of Methods for Correcting QT Interval in Athletes and Young People: A Systematic Review. Clin Cardiol. 2023;46(9):1106-1115.
  8. Andrsova I, Hnatkova K, Sisakova M, et al. Influence of Heart Rate Correction Formulas on QTc Interval Stability. Sci Rep. 2021;11(1):14269.
  9. Idiazabal-Ayesa U, Guia-Galipienso F, Sanz-de la Garza M, et al. Influences of Age, Sex, and Heart Rate on Corrected QT Interval Values Calculated by Using Bazett and Fridericia Formulas in Children and Young Adolescent Athletes. Clin J Sport Med. 2025.
  10. Schwartz PJ, Ackerman MJ, George AL, Wilde AAM. Impact of Genetics on the Clinical Management of Channelopathies. J Am Coll Cardiol. 2013;62(3):169-180.
  11. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. J Am Coll Cardiol. 2017;70(5):e39-e110.
  12. Schwartz PJ, Crotti L. Long QT Syndrome. N Engl J Med. 2025;393(20):2023-2034.
  13. Wilde AAM, Semsarian C, Marquez MF, et al. European Heart Rhythm Association/Heart Rhythm Society/APHRS/LAHRS Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022;19(7):e1-e60.
  14. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Heart Rhythm. 2018;15(10):e73-e189.
  15. Shah MJ, Silka MJ, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Heart Rhythm. 2021;18(11):1888-1924.
  16. Silka MJ, Shah MJ, et al. 2021 PACES Expert Consensus Statement: Executive Summary. Heart Rhythm. 2021;18(11):1925-1950.
  17. Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233.
  18. Page RL, O'Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(6):e32-69.
  19. Warrings W, Taurines R, Egberts K, et al. Correlation Between Escitalopram, Sertraline, and Fluoxetine Serum Levels and QTc Interval Prolongation in Children and Adolescents. Ther Drug Monit. 2025.

Related Calculators

QTc IntervalCardiology